Iron Leap
Iron Leap provides gastrointestinal biospecimens paired with curated clinical context for biopharma and AI researchers. The company offers retrospective FFPE tissue collections and prospective collection pathways, with EHR-derived annotation connecting samples to diagnosis, treatment history, and longitudinal patient data to support biomarker discovery and translational research.
- Biotechnology
- Healthcare Technology
- Drug Discovery & Therapeutics
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Biopharma and AI researchers working on gastrointestinal diseases often lack access to high-quality tissue samples that are accompanied by detailed, structured clinical data. Archived FFPE blocks and prospectively collected specimens are frequently disconnected from treatment history, pathology reports, and longitudinal patient context, limiting the ability to build robust datasets for biomarker discovery and translational research.
Solution
Iron Leap bridges this gap by connecting GI biospecimens with carefully curated clinical context from care partners, enabling researchers to build more meaningful and study-aligned datasets. The company offers two distinct collection pathways: retrospective access to archived formalin-fixed, paraffin-embedded (FFPE) tissue blocks with available clinical histories, and prospective collections designed around a study’s specific eligibility criteria, specimen requirements, and consent/protocol needs. Tissue is paired with EHR-derived annotation that can include diagnosis, treatment history, pathology findings, and longitudinal context. This helps researchers ask better questions and supports biomarker discovery, translational drug development, and AI research.
Target Audience
Primary customers are biopharma companies and AI researchers who need study-aligned GI biospecimens with rich clinical context for biomarker discovery and translational drug development.
Features
- GI disease focus including inflammatory bowel disease (Crohn’s disease and ulcerative colitis), eosinophilic esophagitis, and broader GI research with study-specific sourcing
- Retrospective FFPE tissue collection from archived blocks paired with available clinical history
- Prospective collection pathways aligned with study eligibility criteria, specimen requirements, and applicable consent and protocol needs
- EHR-derived annotation linking specimens to diagnosis, treatment history, pathology findings, and longitudinal context
- Ethics-led collaboration across community practices, pathology labs, and hospitals